We recently published a list of Jim Cramer’s Thoughts on These 7 Stocks. In this article, we are going to take a look at ...

A couple of months ago, healthcare equity research analyst Jared Holz from Mizuho spoke about Viking potentially being an acquisition target. During his discussion, Holz suggested that Viking could ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $33.69, moving +0.78% from the previous trading session.

Since VKTX is devoid of marketed drugs, investors will focus on pipeline updates when it reports Q4 results next week.

First Solar will report financial results for the fourth quarter and full year ended Dec. 31, 2024, after the closing bell on ...

Viking Therapeutics (NASDAQ:VKTX – Get Free Report) is expected to release its earnings data after the market closes on ...

In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), ...

Viking Therapeutics struggles with FDA approval and scaling up. Find out why VKTX stock’s path remains uncertain, despite its ...

其他开发GLP-1药物的公司包括阿斯利康（AZN.US）、安进（AMGN.US）、辉瑞（PFE.US）、罗氏、Altimmune （ALT.US）、Viking Therapeutics （VKTX.US）、Zealand 、Terns Pharmaceuticals （TERN.US）和Structure Therapeutics （GPCR.US）。